Publicatinos / Presentations
- October 25, 2025 AACR-NCI-EORTC 2025
Preclinical and clinical activity of VRN101099, Novel Covalent HER2 TKI for HER2-Positive/Mutant Metastatic Solid Tumors
- October 23, 2025 AACR-NCI-EORTC 2025
VRN110755, a CNS-penetrant EGFR inhibitor, demonstrates clinical activity in EGFR-mutant NSCLC, including C797S and brain metastases, with a favorable safety profile
- October 23, 2025 AACR-NCI-EORTC 2025
A Phase 1,2 Study of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
- October 23, 2025 AACR-NCI-EORTC 2025
A Phase 1, First-in-Human, Dose-Escalation Study of VRN101099, a Brain-Penetrant HER2 TKI, in Patients with Advanced HER2 Alteration Solid Tumors
- April 2025 AACR 2025
First-in-human Studies of VRN110755 in NSCLC Patients with EGFR Mutations: Safety, Pharmacokinetics, and Early Efficacy Assessment
- April 2025 AACR 2025
VRN16: A novel PKMYT1 selective kinase inhibitor with wide therapeutic window
- April 2025 AACR 2025
VRN19: A novel USP1 Inhibitor with anti-tumor efficacy and favorable safety profile
- April 2025 AACR 2025
VRN101099: a novel treatment option for HER2-driven cancer patients, overcoming T-DXd resistance and brain metastases
- October 2024 ENA 2024
VRN101099: a novel oral treatment option for patients with advanced solid tumors including brain metastasis driven by HER2 amplification or HER2-activating mutations even with T-DXd resistance
- October 2024 ENA 2024
ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates Best-in-Class properties against exon 20 insertions and other atypical EGFR mutations
- October 2023 ESMO 2023
A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR and HER2 exon 20 or HER2 alterations
- September 2023 WCLC 2023
VRN110755, A New Therapeutic Option for EGFR Mutation-Driven NSCLC with Brain Metastasis or 1st-line Osimertinib-Resistant EGFR Mutations
- April 2022 AACR 2022
ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetration and antitumor activity in subcutaneous and intracranial NSCLC models
- April 2021 AACR 2021
ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor selectively targets EGFR and HER2 exon 20 insertion mutants and regresses intracranial NSCLC Xenograft tumors